Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 15816231

Angiosarcoma replacing bone marrow--a case report.

R Arnold Smith·Sergey A Dzugan·Syed Rafique·Marsha Lucas
View original source ↗Export metadata ↓

Abstract

BACKGROUND: Clinical syndromes caused by marrow replacement by neoplastic cells are usually proven to arise from cells of hematopoetic or carcinomatous lineage. Diffuse marrow replacement by mesodermal origin sarcoma is rare in adults, and angiosarcoma replacing bone marrow is a very rare neoplasm. METHODS: A case of bone marrow replacement by angiosarcoma in a 54-year-old African American man is described with a review of pertinent literature. The unique histopathologic features of this phenomenon are also described. RESULTS: Histopathologic exam of trephine bone marrow biopsy revealed replacement of marrow spaces by a proliferating highly vascular malignant neoplasm with features of high-grade angiosarcoma. CONCLUSION: Few reports in the literature describe angiosarcomatosis of the bone marrow. It is important to recognize this unusual presentation to avoid confusion with other more common bone marrow replacing entities and to promote recognition that more efficacious treatment is needed.

Explore related subjects

Bone Marrow NeoplasmsFatal OutcomeHemangiosarcomaHumansMaleMiddle AgedCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Arnold Smith, Sergey A Dzugan, Syed Rafique, Marsha Lucas. 2005. Angiosarcoma replacing bone marrow--a case report.. https://pubmed.ncbi.nlm.nih.gov/15816231/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

CXCL12 does not attract CXCR4+ human metastatic neuroblastoma cells: clinical implications.

PURPOSE: The role of CXCR4 in bone marrow localization of neuroblastoma cells has been recently proposed. The aim of this study was to investigate the expression and chemotactic functionality of CXCR4 in human metastatic neuroblastoma cells isolated from the bone marrow and, for comparison, in a panel of neuroblastoma cell lines. EXPERIMENTAL DESIGN: CXCR4 expression and chemotactic functionality were investigated in metastatic neuroblastoma cells isolated from patient bone marrow and in neuroblastoma cell lines. The former cells were isolated as CD45- or GD2+ cells by immunomagnetic bead manipulation. Chemotactic assays were done in a transwell system. Regulator of G protein signaling expression was investigated by reverse transcription-PCR. RESULTS: Metastatic neuroblastoma cells consistently expressed CXCR4, which was also detected in 5 of 10 neuroblastoma cell lines. CXCL12 did not stimulate the chemotaxis of primary tumor cells or cell lines in either normoxia or hypoxia, irrespective of CXCR4 up-regulation detected under the latter condition. Accordingly, neuroblastoma cells failed to modulate filamentous actin and to activate mitogen-activated protein kinase upon treatment with CXCL12. RGS16 mRNA was consistently expressed in primary tumor cells and cell lines, but its down-regulation by RNA interference did not restore CXCR4 chemotactic functionality. CONCLUSIONS: These results show unambiguously that CXCR4 expressed in human metastatic neuroblastoma cells is not functional and do not support the clinical use of CXCR4 antagonists to prevent neuroblastoma metastasis.

Bone Marrow Neoplasms↗
PubMed2006

Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients.

BACKGROUND: We reviewed clinical and biologic findings in a series of infants with neuroblastoma (NB) in liver. The aim was to gain insights into improving therapy. PATIENTS AND METHODS: Among 19 newly or recently diagnosed infants with NB in liver, 1987-2002, those with stage 4 involving bone received chemotherapy, while those without bone or extensive bone marrow (BM) involvement were observed or received limited treatment if NB caused life-threatening symptoms. We assessed results in the context of NB treatment risk stratification, which is based on age, stage, and selected biologic features (MYCN, ploidy, histology). RESULTS: Six of eight infants with bone involvement became long-term event-free survivors including 1/2 with MYCN amplification and four who received only 4-6 cycles of chemotherapy; at the end of treatment, four infants had abnormalities in liver +/- the primary site, but these resolved. All 11 infants without bone lesions became long-term survivors with either no cytotoxic therapy or only one cycle of chemotherapy (+/- radiotherapy to liver), including four who had stage 4 and one stage 4S patient who still had NB in BM at age 15 months. CONCLUSIONS: Treatment reduction should be considered for subsets of infants with non-MYCN-amplified widespread NB: stage 4 without bone or extensive BM involvement may not require cytotoxic therapy, stage 4S with symptomatic hepatomegaly may not require multiple cycles of chemotherapy, and classic stage 4 may do well with limited chemotherapy. Persistent liver abnormalities post-treatment may not require continued therapy to achieve a radiologic complete remission.

Bone Marrow Neoplasms↗